OR WAIT null SECS
© 2022 MJH Life Sciences and BioPharm International. All rights reserved.
© 2022 MJH Life Sciences™ and BioPharm International. All rights reserved.
Associate Professor in the Industrial Biochemistry Program at the University of Limerick. He is also a member of BioPharm International's Editorial Advisory Board.
A review of the past year's trends in biopharmaceutical approvals shows an above average approval rate.
First gene therapy and plant-based expression vector products approved in 2012.
A review of new biologic drug approvals over the years, featuring highlights from 2010 and 2011.
Biotech approvals were up last year. Is it a sign of a new trend?
Ten biopharmaceuticals gained marketing authorization in the US or EU in 2008, although only four were new approvals.
The year 2007 witnessed the approval of fifteen biopharmaceuticals in the United States and European Union.
The book is a useful, comprehensive, and truly an excellent reference source of biopharmaceutical information.
An overall increasing proportion of future product approvals will be engineered in some way, either directly or indirectly.
There were notable approvals in nonparenteral delivery systems and biosimiliars in 2006.
In 2005, 10 biopharma- ceuticals gained marketing approval in the US or Europe, although only five of them were genuinely new molecular entities.